- Home
- SHLS vs LENZ Comparison
SHLS vs LENZ Comparison
Compare SHLS & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHLS
- LENZ
- Stock Information
- Founded
- SHLS 1996
- LENZ 2019
- Country
- SHLS United States
- LENZ United States
- Employees
- SHLS N/A
- LENZ N/A
- Industry
- SHLS Semiconductors
- LENZ Medicinal Chemicals and Botanical Products
- Sector
- SHLS Technology
- LENZ Health Care
- Exchange
- SHLS Nasdaq
- LENZ Nasdaq
- Market Cap
- SHLS 951.6M
- LENZ 886.2M
- IPO Year
- SHLS 2021
- LENZ 2021
- Fundamental
- Price
- SHLS $4.56
- LENZ $33.20
- Analyst Decision
- SHLS Buy
- LENZ Strong Buy
- Analyst Count
- SHLS 18
- LENZ 6
- Target Price
- SHLS $12.14
- LENZ $35.40
- AVG Volume (30 Days)
- SHLS 5.3M
- LENZ 185.6K
- Earning Date
- SHLS 11-12-2024
- LENZ 11-06-2024
- Dividend Yield
- SHLS N/A
- LENZ N/A
- EPS Growth
- SHLS N/A
- LENZ N/A
- EPS
- SHLS 0.19
- LENZ N/A
- Revenue
- SHLS $422,657,000.00
- LENZ N/A
- Revenue This Year
- SHLS N/A
- LENZ N/A
- Revenue Next Year
- SHLS $17.85
- LENZ N/A
- P/E Ratio
- SHLS $23.49
- LENZ N/A
- Revenue Growth
- SHLS N/A
- LENZ N/A
- 52 Week Low
- SHLS $4.53
- LENZ $2.12
- 52 Week High
- SHLS $17.50
- LENZ $38.93
- Technical
- Relative Strength Index (RSI)
- SHLS 37.00
- LENZ 60.99
- Support Level
- SHLS $4.64
- LENZ $28.07
- Resistance Level
- SHLS $5.36
- LENZ $38.93
- Average True Range (ATR)
- SHLS 0.44
- LENZ 2.64
- MACD
- SHLS -0.08
- LENZ 0.36
- Stochastic Oscillator
- SHLS 1.82
- LENZ 55.27
About SHLS Shoals Technologies Group Inc.
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
About LENZ LENZ Therapeutics Inc. Common Stock
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.